GLP-1 receptor agonists have been proven to be associated with significant beneficial cardiovascular effects, improvement in non-alcoholic fatty liver disease, and diabetic nephropathy [68,73,74]. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.